Logo

Abbott Presents Results of Freestyle Libre 3 System for the Treatment of Type 1 or Type 2 Diabetes at ADA 2022

Share this
Abbott Presents Results of Freestyle Libre 3 System for the Treatment of Type 1 or Type 2 Diabetes at ADA 2022

Abbott Presents Results of Freestyle Libre 3 System for the Treatment of Type 1 or Type 2 Diabetes at ADA 2022

Shots:

  • The company reported the results from the clinical study to evaluate the accuracy of the FreeStyle Libre 3 system in patients aged ≥4yrs. with T1D or T2D who were on insulin therapy
  • The results showed that Abbott's FreeStyle Libre 3 system marks the first and only 14-day continuous glucose monitor (CGM) system to achieve a mean absolute relative difference (MARD) of ≥8%, MARD values were 7.6% for adults (aged ≥18yrs.); 8.7% & 10.1% for children (aged 6-17yrs. & 4-5yrs.)
  • In an additional analysis, the results also showed the positive impact of the FreeStyle Libre system and LibreView app in assisting healthcare providers in making early treatment decisions and recognizing hypoglycemia events

Ref: Abbott | Image: Abbott

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions